Cryopreserved Pre-embryo Transfer in a Cytokine-rich Medium Versus Hyaluronic Acid (CSF-EG)
Transferencia de Preembriones Criopreservados en un Medio Rico en Citoquinas Versus ácido hialurónico: Estudio clínico Aleatorizado
This multicenter, randomized, double-blind study compares a GM-CSF-enriched embryo transfer medium with a hyaluronic acid-enriched medium in women undergoing single frozen embryo transfer. It will assess whether the GM-CSF medium is non-inferior for clinical pregnancy rates. Participants will be randomly assigned to one of the two groups.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Hyaluronic acid is commonly used in embryo transfer media to support embryo-endometrial adhesion. GM-CSF is a cytokine that may help regulate cellular stress and apoptosis after embryo warming. This study will compare a GM-CSF-supplemented transfer medium with a hyaluronic acid-supplemented medium in frozen embryo transfer cycles. Its primary aim is to determine whether the GM-CSF medium is non-inferior to the hyaluronic acid medium for clinical pregnancy. The results may help inform the choice of transfer medium in assisted reproduction.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Nicolás Prados Dodd
- Phone Number: +34 954 28 62 74
- Email: vida.investiga@gruporecoletas.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women aged 18 to 50 years.
- Undergoing transfer of a single cryopreserved embryo (SET) from own and/or donor gametes.
Exclusion Criteria:
- Uterine malformations or conditions that, in the physician's judgment, could affect implantation.
- Transfer of more than one embryo.
- Transfer of mosaic embryos.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: GM-CSF-supplemented transfer medium
Participants receive a single frozen embryo transfer using SAGE 1-Step medium with GM-CSF. |
Embryo transfer medium enriched with cytokines, used for the transfer of cryopreserved embryos. |
|
Active Comparator: Hyaluronic acid-enriched transfer medium
Participants receive a single frozen embryo transfer using EmbryoGlue medium enriched with hyaluronic acid. |
Embryo transfer medium enriched with hyaluronic acid, used for the transfer of cryopreserved embryos. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical pregnancy rate per embryo transfer
Time Frame: 6-9 weeks of gestation after embryo transfer.
|
Proportion of embryo transfers resulting in an intrauterine gestational sac and fetal heartbeat confirmed by ultrasound. |
6-9 weeks of gestation after embryo transfer.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biochemical pregnancy rate per embryo transfer
Time Frame: 9-15 days after embryo transfer.
|
Proportion of participants with a positive serum β-hCG test after embryo transfer. |
9-15 days after embryo transfer.
|
|
Ongoing pregnancy rate per embryo transfer
Time Frame: 6-9 weeks of gestation after embryo transfer.
|
Proportion of participants with embryonic heartbeat detected. |
6-9 weeks of gestation after embryo transfer.
|
|
Live birth rate per embryo transfer
Time Frame: From embryo transfer through delivery, up to 9 months after embryo transfer.
|
Proportion of participants with a live-born infant at delivery. |
From embryo transfer through delivery, up to 9 months after embryo transfer.
|
|
Biochemical pregnancy loss rate per embryo transfer
Time Frame: From serum β-hCG testing at 9-15 days after embryo transfer through ultrasound assessment at 6-9 weeks of gestation.
|
Pregnancy loss after a positive or indeterminate β-hCG result, without ultrasound confirmation of a gestational sac. |
From serum β-hCG testing at 9-15 days after embryo transfer through ultrasound assessment at 6-9 weeks of gestation.
|
|
Clinical pregnancy loss rate per embryo transfer
Time Frame: After ultrasound confirmation of the gestational sac; the protocol does not specify a final follow-up time point.
|
Pregnancy loss after an intrauterine gestational sac has been confirmed. |
After ultrasound confirmation of the gestational sac; the protocol does not specify a final follow-up time point.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2601_VAL_MA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data will not be shared with other researchers. Study results will be disseminated through publications and presentations in aggregate form.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.